"Spironolactone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
| Descriptor ID |
D013148
|
| MeSH Number(s) |
D02.540.679 D04.210.500.745.745.855
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Spironolactone".
Below are MeSH descriptors whose meaning is more specific than "Spironolactone".
This graph shows the total number of publications written about "Spironolactone" by people in this website by year, and whether "Spironolactone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 3 | 1 | 4 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 1 | 2 |
| 2021 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Spironolactone" by people in Profiles.
-
Gandotra C, Clark J, Liu Q, Senatore FF, Rose M, Zhang J, Stockbridge NL. Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective. Ther Innov Regul Sci. 2022 01; 56(1):4-7.
-
Aryal SR, Siddiqui M, Sharifov OF, Coffin MD, Zhang B, Gaddam KK, Gupta H, Denney TS, Dell'Italia LJ, Oparil S, Calhoun DA, Lloyd SG. Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change. J Am Heart Assoc. 2021 09 07; 10(17):e019434.
-
Wang Y, Wang J, Yang R, Wang P, Porche R, Kim S, Lutfy K, Liu L, Friedman TC, Jiang M, Liu Y. Decreased 11?-Hydroxysteroid Dehydrogenase Type 2 Expression in the Kidney May Contribute to Nicotine/Smoking-Induced Blood Pressure Elevation in Mice. Hypertension. 2021 06; 77(6):1940-1952.
-
Calhoun DA. Fluid retention, aldosterone excess, and treatment of resistant hypertension. Lancet Diabetes Endocrinol. 2018 06; 6(6):431-433.
-
Calhoun DA. Medical Versus Surgical Treatment of Primary Aldosteronism. Hypertension. 2018 04; 71(4):566-568.
-
Siddiqui M, Judd EK, Oparil S, Calhoun DA. White-Coat Effect Is Uncommon in Patients With Refractory Hypertension. Hypertension. 2017 09; 70(3):645-651.
-
Graves R, Phan KV, Bostanian LA, Mandal TK, Pramar YV. Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt. Int J Pharm Compd. 2017 Jul-Aug; 21(4):334-338.
-
Dudenbostel T, Calhoun DA. Effects of Spironolactone and Renal Denervation Treatment on Blood Pressure and Its Variability-Different Aspects of Hypertension Treatment. Am J Hypertens. 2017 01; 30(1):12-15.
-
Calhoun DA. Spironolactone versus renal nerve denervation for treatment of uncontrolled resistant hypertension. J Hypertens. 2016 09; 34(9):1701-3.
-
Ghazi L, Dudenbostel T, Lin CP, Oparil S, Calhoun DA. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. J Hypertens. 2016 May; 34(5):1005-10.